Rekom Biotech has attended to MEDICA 2018. The fair was held in Düsseldorf from November 12th to 15th, 2018. The fair allowed us to consolidate the relationship with our customers as well as to explore new strategic alliances. In addition, we have been able to observe the new trends of the IVD market.
Rekom Biotech has attended the 70th AACC Clinical Lab Expo. In this occasion, the trade show was held in Chicago from 31st July to 2nd August. As in previous AACC meetings, the visit had as purpose to consolidate Rekom Biotech’s presence in the US Market and other countries. During the exhibition, our colleagues, Dr. Ana Camacho (CEO & CSO - Ph.D.) and María J. Clavijo (Export Manager), met with customers and potential ones interested in our recombinant antigens range, recombinant allergens range (bio-allergens line), and our custom-made design services. The event has been another successful meeting for Rekom Biotech and we thank all the companies we met with at the trade show. We look forward to the next AACC Clinical Lab Expo.
Rekom Biotech attends to MEDLAB ASIA PACIFIC, from 2nd to 4th April, 2018, aiming to consolidate their presence in the Asian market. During the exhibition, our colleagues, Dr. Ana Camacho (CEO & CSO - PhD) and Rafael Texeira (Export Manager), met potential customers interested both in our recombinant antigens range and our custom-made design services. Furthermore, the new recombinant allergens range (bioallergens line), was introduced and current customers from countries such as China, India or Japan were visited.
Rekom Biotech has again attended MEDICA, from 13rd to 16th November, 2017. This year we have presented our new range of recombinant allergens range (bio-allergens line), in addition to our recombinant antigens most successful in evaluations for the development of a commercial diagnostic assay.
Rekom Biotech has participated one more year in Clinical Lab Expo, from August 1st to 2nd, 2017. As always, it has been a pleasure to visit our customers and distributors, as well as establish new collaborations.